Breakthrough Award – Level 1 – HT942526BCRPBTA122
- Letters of Intent due 4 November 2026
- Up to USD$750,000 (Single PI) or up to USD$1.25M (Partnering PI option) over 3 years
- supports promising research with high potential to lead to or make breakthroughs in breast cancer
- research must have the potential for a major impact and accelerate progress toward ending breast cancer
- supports innovative, high-risk/high-reward research that is in the earliest stages of idea development
- anticipated outcome is proof of concept
- Partnering PI option supports meaningful and productive partnerships between two PIs
- Preliminary data not required
- Clinical research including projects involving human data, human anatomical substances and/or interaction with human subjects is allowed
- Clinical trials are not allowed
- Must address at least one of the overarching challenges
- Apply here
- Document – Program Announcement – HT942526BCRPBTA122_GG
Breakthrough Award – Level 2 – HT942526BCRPBTA122
- Letters of Intent due 4 November 2026
- Up to USD$1.65M (Single PI) or up to USD$2.5M (Partnering PI option) over 3 years
- supports promising research with high potential to lead to or make breakthroughs in breast cancer
- research must have the potential for a major impact and accelerate progress toward ending breast cancer
- supports research already supported by substantial preliminary or published data in breast cancer and strongly validates clinical translation
- Partnering PI option supports meaningful and productive partnerships between two PIs
- Preliminary/published data required
- Clinical research including projects involving human data, human anatomical substances and/or interaction with human subjects is allowed
- Clinical trials are not allowed
- Must address at least one of the overarching challenges
- Apply here
- Document – Program Announcement – HT942526BCRPBTA122_GG
Breakthrough Award – Level 2 – Population Studies HT942526BCRPBTA122
- Letters of Intent due 4 November 2026
- Up to USD$2.5M (Single PI) or up to USD$3.35M (Partnering PI option) over 4 years
- supports promising research with high potential to lead to or make breakthroughs in breast cancer
- research must have the potential for a major impact and accelerate progress toward ending breast cancer
- supports studies analysing human data and biospecimens for research that is already supported by substantial preliminary or published data in breast cancer and strongly validates clinical translation
- Partnering PI option supports meaningful and productive partnerships between two PIs
- Preliminary/published data required
- Clinical research including projects involving human data, human anatomical substances and/or interaction with human subjects is allowed
- Clinical trials are not allowed
- Must address at least one of the overarching challenges
- Apply here
- Document – Program Announcement – HT942526BCRPBTA122_GG
Clinical Research Extension Award – HT942526BCRPCREA2
- Letters of Intent due 4 November 2026
- up to USD$7M (Single PI) or up to USD$8.4M (Partnering PI option) over 4 years
- supports projects entailing a deeper molecular analysis of clinical samples, initiation of new correlative studies, biomarker validation or continuing clinical follow-up of patients enrolled in an open/ongoing or completed clinical trial or study
- proposed research may be hypothesis-testing or generating or may be designed to generate experimental platforms
- Partnering PI option supports meaningful and productive partnerships between two PIs
- Projects proposing initiation of new clinical trials or studies, or increasing enrolment in existing studies not allowed
- Must include two or more breast cancer advocates on the research team
- Apply here
- Document – Program Announcement – HT942526BCRPCREA2_GG
Overarching Challenges
- Prevent breast cancer (primary prevention)
- Identify determinants of breast cancer initiation, risk, or susceptibility
- Distinguish deadly from non-deadly breast cancers
- Conquer the problems of overdiagnosis and overtreatment
- Identify what drives breast cancer growth; determine how to stop it
- Identify why some breast cancers become metastatic
- Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence
- Revolutionize treatment regimens by replacing them with ones that do all of the following: improve survival, are more effective, and are less toxic
- Eliminate the mortality associated with metastatic breast cancer
